On December 8th, Shanghai Huiyueyan Biotechnology Co., Ltd. (referred to as “Huiyueyan”) announced the completion of a nearly 100 million RMB angel round financing. This round of financing was jointly invested by Longriver Investments and Rockbleu Capital, with Haoyue Capital serving as the exclusive financial advisor for this round of financing.
Public information shows that Huiyueyan was established in 2023. The research and development team has over 20 years of experience in the field of polymer materials. They continuously innovate based on a core technology platform and have a successful track record of product development and commercialization. They have previously received angel round investments from Goldman Sachs (China), Junlian Capital, Arctic Light Ventures, Yuanju Capital, Puregene Biotech, and others.
Longriver Investments stated that Huiyueyan has deep strategic deployment in the anti-aging and regeneration product category. We have great confidence in the differentiated advantages of Huiyueyan’s product pipeline and look forward to the company further unleashing its innovative potential and creating a highland in aesthetics.
Mr. Yang Zhenjun, Managing Partner of Haoyue Capital, said, “Huiyueyan relies on its team’s years of research and development experience in the field of high-end interventional implantable medical consumables. They have a high barrier degradable polymer material product conversion platform and operate as a platform-based medical beauty enterprise focused on technological innovation, product compliance, and continuous iteration. We look forward to Huiyueyan fully leveraging its technological and team advantages to become a leading value creator in the field of medical beauty products.”
